ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Rhea-AI Summary

Oragenics (NYSE American: OGEN) is exploring acquisition of CNS assets focused on brain health and brain recovery to complement its intranasal delivery platform and lead candidate ONP-002.

ONP-002 Phase IIa is in active site initiation in Australia; Phase 1 showed safety in 40 patients with zero serious adverse events. No definitive acquisition agreements have been reached; any material transaction will be disclosed as required.

Positive

• Phase IIa initiation in Australia for ONP-002 with active site initiation
• Phase 1 safety data: 40 patients with zero serious adverse events
• Strategic pursuit of CNS assets to leverage proprietary intranasal delivery platform

Negative

• No definitive acquisition agreements; no assurance any transaction will complete
• Planned U.S. IND submission for ONP-002 not expected until 2027, extending development timeline

News Market Reaction – OGEN

-9.90% 3.2x vol

25 alerts

-9.90% News Effect

+7.8% Peak Tracked

-17.5% Trough Tracked

-$508K Valuation Impact

$4.63M Market Cap

3.2x Rel. Volume

On the day this news was published, OGEN declined 9.90%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -17.5% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $508K from the company's valuation, bringing the market cap to $4.63M at that time. Trading volume was very high at 3.2x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase IIa trial stage: Phase IIa Additional trial sites: 2 sites Phase 1 safety population: 40 patients +2 more

5 metrics

Phase IIa trial stage Phase IIa ONP-002 concussion and mild traumatic brain injury trial in Australia

Additional trial sites 2 sites Two Australian sites completing final Research Governance reviews

Phase 1 safety population 40 patients Phase 1 ONP-002 safety and tolerability study

Serious adverse events 0 events Phase 1 ONP-002 safety results in 40 patients

Planned IND timing 2027 Target year to submit IND to FDA after Phase IIa in Australia

Market Reality Check

Price: $0.5601 Vol: Volume 315,897 is 0.7x th...

normal vol

$0.5601 Last Close

Volume Volume 315,897 is 0.7x the 20-day average of 450,966, indicating subdued trading ahead of this update. normal

Technical Shares at 0.9816 are trading below the 200-day MA of 1.49 and 89.77% under the 52-week high of 9.6.

Peers on Argus

OGEN was up 2.23% with relatively light volume, while momentum peers were split ...

1 Up 1 Down

OGEN was up 2.23% with relatively light volume, while momentum peers were split (e.g., ADTX up 7.69%, PALI down 3.13%). Broader biotech peers such as XBIO, GRI, and ONCO showed mixed positive moves, with others like APVO and QNRX down, suggesting stock-specific rather than sector-wide drivers.

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Phase IIa approval	Positive	+2.2%	Final HREC approval in Australia for ONP-002 Phase IIa concussion trial.
Feb 09	Program milestones	Positive	-5.2%	Outlined 2026 milestones and funding status for ONP-002 concussion program.
Feb 03	Regulatory partnership	Positive	-7.2%	Engaged DUCK FLATS Pharma to support FDA IND readiness and trial design.
Feb 02	Conference participation	Neutral	-0.0%	Participation in SCOPE Summit 2026 to support upcoming Australian trial.
Jan 14	Investor summit	Positive	+4.7%	Presentation at Sequire Investor Summit on ONP-002 clinical plans.

Pattern Detected

Recent news has produced mixed reactions: some positive regulatory and trial updates aligned with gains, while other constructive clinical and strategic releases were followed by pullbacks.

Recent Company History

Over the past few months, OGEN has steadily communicated progress around ONP-002, including HREC approval on Mar 10, 2026 and IND-readiness partnerships and conferences in early 2026. Price reactions have varied, with both gains and selloffs on ostensibly positive clinical and strategic news. Today’s CNS portfolio expansion update builds on this sequence of concussion-focused development milestones and platform positioning around intranasal brain-targeted therapeutics.

Regulatory & Risk Context

Active S-3 Shelf · $100,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-22

$100,000,000 registered capacity

An effective Form S-3 shelf filed on 2026-01-22 allows Oragenics to offer up to $100,000,000 of securities, including $34,156,040 carried over from a prior shelf. As of Jan 21, 2026, the public float was about $4,222,535, limiting primary offerings under this shelf to no more than one‑third of that float in any twelve‑month period unless the float rises to at least $75.0 million.

Market Pulse Summary

The stock moved -9.9% in the session following this news. A negative reaction despite expansion news...

Analysis

The stock moved -9.9% in the session following this news. A negative reaction despite expansion news would fit a pattern where prior positive ONP-002 updates sometimes coincided with selling. The release framed ONP-002 as Phase IIa-ready with earlier Phase 1 safety in 40 patients and no serious adverse events, plus a planned FDA IND in 2027. However, uncertainty around potential asset deals and an unused $100,000,000 shelf could have amplified downside concerns.

Key Terms

central nervous system (cns), intranasal delivery, neuroinflammation, oxidative stress, +4 more

8 terms

central nervous system (cns) medical

"acquisition of additional assets in the central nervous system (CNS) space"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

intranasal delivery medical

"brain-targeted therapeutics through proprietary intranasal delivery technology"

A method of giving a drug or vaccine through the nose using sprays, drops, or inhaled particles so the medicine is absorbed by nasal tissues and can enter the bloodstream or reach the brain more directly than an oral pill. Investors care because intranasal delivery can speed onset, avoid needles, lower manufacturing or distribution costs, and open new markets for treatments that are hard to administer by mouth or injection—factors that affect a product's commercial potential and regulatory path.

neuroinflammation medical

"reducing neuroinflammation, oxidative stress, and cerebral edema at the source"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

oxidative stress medical

"reducing neuroinflammation, oxidative stress, and cerebral edema at the source"

Oxidative stress is a biological imbalance where damaging, unstable molecules overwhelm the body’s neutralizing defenses, similar to how rust forms when metal is exposed to oxygen and moisture. Investors should care because oxidative stress is linked to many diseases and aging processes, influencing demand for drugs, diagnostics, supplements, and healthcare spending, and it can affect the commercial value and regulatory outlook of related products.

cerebral edema medical

"reducing neuroinflammation, oxidative stress, and cerebral edema at the source"

Cerebral edema is swelling of the brain caused by excess fluid, like a sponge expanding inside a closed jar. It can impair brain function and be life-threatening, so its occurrence or risk is closely watched in drug trials and medical-device testing. For investors, reports of cerebral edema can influence regulatory decisions, product labels, potential liability and market value because they affect a therapy’s safety profile, development timeline and commercial prospects.

phase iia medical

"advancing ONP-002 through Phase IIa in Australia and into U.S.-based Phase IIb trials"

Phase IIa is an early mid-stage clinical study that tests whether a new drug or treatment shows the intended biological effect in patients and helps identify the best dose. Think of it as a focused test-drive to see if a medicine does what it’s supposed to and what dose is tolerable before larger trials. Investors watch Phase IIa results because positive findings reduce technical risk and can materially increase the program’s value, while negative results raise the likelihood of costly delays or failure.

phase iib medical

"Phase IIa in Australia and into U.S.-based Phase IIb trials"

Phase IIb is a mid-stage clinical trial that tests whether an experimental treatment works and what dose is best by studying it in a larger group of patients than early tests. For investors, Phase IIb results are important because they substantially reduce uncertainty about a drug’s effectiveness and safety, and positive or negative outcomes often drive company valuation, partnership interest, and the likelihood of advancing to the large, costly Phase III trials.

ind application regulatory

"plans to submit an IND application to the FDA for continued US based clinical trials"

An Investigational New Drug (IND) application is a formal request to regulators to allow a drug or biologic to be tested in people. It bundles lab and animal safety data, manufacturing details, and a plan for human trials—think of it like a building permit that lets developers move from design to construction. For investors, IND approval is a key milestone that permits clinical testing, reduces regulatory uncertainty, and can materially affect a company’s timeline, risk profile, and valuation.

AI-generated analysis. Not financial advice.

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company's lead candidate ONP-002 and its proprietary intranasal drug delivery platform.

The Company's portfolio expansion initiative is being pursued independently of its existing partnership with Receptor.AI, which focuses on artificial intelligence-enabled CNS drug discovery. Together, these two parallel strategies — traditional asset acquisition and AI-driven discovery — reflect Oragenics desire to build a diversified, platform-anchored CNS portfolio.

No definitive agreements have been reached, and there can be no assurance that any transaction will be completed on terms acceptable to the Company, or at all. The Company will disclose any material transaction in accordance with applicable securities laws and regulations.

STRATEGIC RATIONALE

Oragenics’ CNS portfolio expansion strategy is grounded in the Company's belief that its proprietary intranasal delivery platform represents a broadly applicable technology with potential across multiple brain health and brain recovery indications. The Company is evaluating acquisition candidates on the following criteria:

• Brain Health and Brain Recovery Focus: Candidates targeting neurological conditions involving brain injury, neuroinflammation, cognitive impairment, or recovery of brain function
• Platform Synergy: Assets that are well-suited for intranasal delivery or that would benefit from the Company's existing CNS regulatory and clinical development capabilities
• Clinical Stage and Data: Candidates with meaningful preclinical or early clinical evidence that can be efficiently advanced through development
• Strategic Fit: Opportunities that complement — without displacing — the Company's commitment to advancing ONP-002 through Phase IIa in Australia and into U.S.-based Phase IIb trials
  
  

ONP-002 PROVIDES THE FOUNDATION

Oragenics’ decision to actively pursue CNS portfolio expansion is grounded in the progress of its lead program. The Phase IIa clinical trial of ONP-002 is now in active site initiation, with the first site initiation visit completed in Australia and two additional sites in Australia completing final Research Governance reviews prior to patient enrollment.

ONP-002 is the only pharmacological candidate in clinical development targeting the underlying biology of concussion and mild traumatic brain injury — reducing neuroinflammation, oxidative stress, and cerebral edema at the source. Phase 1 demonstrated safety and tolerability in 40 patients with zero serious adverse events. There are currently no FDA-approved pharmacological treatments for concussion or mTBI.

Following Phase IIa in Australia, the Company plans to submit an IND application to the FDA for continued US based clinical trials in 2027 to advance the development of ONP-002.

“ONP-002 is advancing in human trials right now – and that progress is exactly what gives us the confidence to continue to look forward. We believe our intranasal delivery platform is not a single-drug asset. It is a technology designed to get therapeutics into the brain rapidly, non-invasively, and effectively. We believe there are real opportunities in the brain health and brain recovery space that could benefit from this platform – some of which we have begun to explore. Our goal isintend to build a CNS company that makes a meaningful impact on how the work treats diseases of the brain. That starts with ONP-002, and it should not stop there.” – Janet Huffman, Chief Executive Officer, Oragenics, Inc.

ABOUT THE INTRANASAL DELIVERY PLATFORM

Oragenics’ proprietary intranasal drug delivery system is designed to enable rapid, non-invasive delivery of therapeutic compounds directly to the brain via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. We believe the platform has the potential to address a fundamental challenge in CNS drug development: delivering therapeutics to the brain with efficiency, speed, and tolerability. Oragenics believes the platform has broad applicability across multiple brain health indications, positioning the Company to build a pipeline anchored in a differentiated and defensible delivery technology.

FORWARD-LOOKING STATEMENTS

This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our product candidates, including without limitation ONP-002 and our proprietary nasal device; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct, interim results announcements and outcomes of our clinical trials for our product candidates, including ONP-002 for the treatment of concussion and mTBI; our acquisition strategy and prospects; and our ability to finance our operations. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project," "potential," "may," "will," "could," "should," and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our most recent Form 10-K, Form 10-Q and other filings we make with the U.S. Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. All information we set forth in this press release is as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.

ABOUT ORAGENICS

Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal drug delivery technology. The Company's lead candidate, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa clinical development for the treatment of concussion and mild traumatic brain injury (mTBI) — conditions affecting an estimated 69 million people globally each year with no approved pharmacological treatment. Oragenics intranasal delivery platform is designed to enable rapid, non-invasive delivery of therapeutics directly to the brain bypassing the blood-brain barrier. The Company is exploring broadening its CNS pipeline strategy through both internal development and strategic business development. For more information, visit www.Oragenics.com.

Investor Contact:
800-383-4880
ir@oragenics.com

FAQ

What CNS assets is Oragenics (OGEN) exploring to expand its platform?

Oragenics is exploring acquisitions targeting brain health and brain recovery indications. According to the company, candidates must suit intranasal delivery, show preclinical or early clinical evidence, and complement ONP-002 without displacing it.

What is the current clinical status of ONP-002 for OGEN?

ONP-002 is in Phase IIa site initiation in Australia with additional sites completing governance reviews. According to the company, Phase 1 enrolled 40 patients with no serious adverse events, supporting further development.

Will Oragenics (OGEN) complete any acquisitions immediately?

No definitive agreements have been reached and transactions are not guaranteed to close. According to the company, discussions are exploratory and any material transaction will be disclosed under securities laws.

When does Oragenics plan to seek FDA clearance to continue ONP-002 trials in the US?

The company plans to submit an IND to the FDA after Phase IIa, targeting continued U.S. trials in 2027. According to the company, this is the intended timeline and remains subject to trial progress.

How does Oragenics’ intranasal platform support potential acquisitions for OGEN?

The intranasal delivery platform is positioned to deliver therapeutics rapidly and non-invasively to the brain. According to the company, this technology could enable efficient development of acquired CNS assets suited for intranasal administration.